SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Shieh, F. K
Right arrow Articles by Sam, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shieh, F. K
Right arrow Articles by Sam, F.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Heart Failure
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Aldosterone and cardiovascular remodelling: focus on myocardial failure

Frederick K Shieh

Boston University Medical School Boston, MA, USA

Eugene Kotlyar

Division of Cardiology, Department of Medicine Boston University Medical Center, Boston, MA, USA

Flora Sam

Boston University Medical School Boston, MA, USA, flora.sam{at}bmc.org, Division of Cardiology, Department of Medicine Boston University Medical Center, Boston, MA, USA

Heart failure is a clinical syndrome that may result from different disease states or conditions that injure the myocardium. The activation of circulating neurohormones, particularly aldosterone, may play a pivotal role in left ventricular (LV) remodelling. The Randomized Aldactone Evaluation Study and Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival trial have emphasised the clinical importance of aldosterone. This review addresses some of the proposed mechanisms of LV remodelling in heart failure.

Key Words: aldosterone • heart failure • myocardial • vascular • remodelling

References

  • Jessup M., Brozena S. Heart failure. N Engl JMed 2003; 348: 2007-18.[Free Full Text]
  • Struthers AD Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J 1995;16(suppl N):103-06.[Abstract]
  • Swedberg K., Eneroth P., Kjekshus J., Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990;82:1730-6.[Abstract/Free Full Text]
  • Mornet E., Dupont J.,Vitek A.,White PC Characterization of two genes encoding human steroid 11 beta-hydroxylase (P-450(11) beta). J Biol Chem 1989; 264:20961-7.[Abstract/Free Full Text]
  • Mizuno Y., Yoshimura M., Yasue H. et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001;103:72-7.[Abstract/Free Full Text]
  • Tsutamoto T.,Wada A., Maeda K. et al. Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol 2000;36:838-44.[Abstract/Free Full Text]
  • Young MJ, Clyne CD, Cole TJ, Funder JW Cardiac steroidogenesis in the normal and failing heart. J Clin Endocrinol Metab 2001;86:5121-6.[Abstract/Free Full Text]
  • Silvestre JS, Robert V., Heymes C. et al. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 1998;273:4883-91.[Abstract/Free Full Text]
  • Takeda Y., Yoneda T., Demura M., Miyamori I., Mabuchi H. Cardiac aldosterone production in genetically hypertensive rats. Hypertension 2000;36:495-500.[Abstract/Free Full Text]
  • Young MJ, Clyne CD, Cole TJ, Funder JW Cardiac steroidogenesis in the normal and failing heart. J Clin Endocrinol Metab 2001;86:5121-6.[Abstract/Free Full Text]
  • Satoh M., Nakamura M., Saitoh H. et al.Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart. Clin Sci (Lond) 2002;102:381-6.[Medline] [Order article via Infotrieve]
  • Yoshimura M., Nakamura S., Ito T. et al. Expression of aldosterone synthase gene in failing human heart: quantitative analysis using modified real-time polymerase chain reaction. J Clin Endocrinol Metab 2002;87:3936-40.[Abstract/Free Full Text]
  • Xiu JC,Wu P., Xu JP et al. Effects of long-term enalapril and losartan therapy of heart failure on cardiovascular aldosterone. J Endocrinol Invest 2002;25:463-8.[Web of Science][Medline] [Order article via Infotrieve]
  • Hanawa H., Abe S., Hayashi M. et al. Time course of gene expression in rat experimental autoimmune myocarditis. Clin Sci (Lond) 2002;103:623-32.[Medline] [Order article via Infotrieve]
  • Kayes-Wandover KM, White PC Steroidogenic enzyme gene expression in the human heart. J Clin Endocrinol Metab 2000;85:2519-25.[Abstract/Free Full Text]
  • Silvestre JS, Robert V., Heymes C. et al. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 1998;273:4883-91.[Abstract/Free Full Text]
  • Young MJ, Moussa L., Dilley R., Funder JW Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 beta-hydroxysteroid dehydrogenase inactivation. Endocrinology 2003;144:1121-5.[Abstract/Free Full Text]
  • Takeda Y., Miyamori I., Yoneda T. et al. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab 1996;81:2797-800.[Abstract/Free Full Text]
  • White PC Aldosterone: direct effects on and production by the heart. J Clin Endocrinol Metab 2003;88:2376-83.[Free Full Text]
  • Lombes M., Oblin ME, Gasc JM, Baulieu EE, Farman N., Bonvalet JP Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 992; 71:503-l0.
  • Lombes M., Alfaidy N., Eugene E.H. Lessana A., Farman N., Bonvalet JP Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation 1995;92:175-82.[Abstract/Free Full Text]
  • Bonvalet JP Regulation of sodium transport by steroid hormones. Kidney Int 1998;65(suppl):S49-S56.
  • Mangelsdorf DJ, Thummel C., Beato M. et al. The nuclear receptor superfamily: the second decade. Cell 1995;83:835-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • White PC, Mune T., Agarwal AK 11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev 1997;18:135-56.[Abstract/Free Full Text]
  • Slight S., Ganjam VK, Nonneman DJ, Weber KT Glucocorticoid metabolism in the cardiac interstitium: 11 beta-hydroxysteroid dehydrogenase activity in cardiac fibroblasts. J Lab Clin Med 1993;122:180-7.[Web of Science][Medline] [Order article via Infotrieve]
  • Kohler E., Bertschin S., Woodtli T., Resink T., Erne P. Does aldosterone-induced cardiac fibrosis involve direct effects on cardiac fibroblasts? J Vasc Res 1996;33:315-26.[Web of Science][Medline] [Order article via Infotrieve]
  • Stockand JD, Meszaros JGAldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-RasA and MAPK1/2 signaling. Am J Physiol Heart Circ Physiol 2003;284:H176-H184.[Abstract/Free Full Text]
  • Fiebeler A., Schmidt F., Muller DN et al. Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury. Hypertension 2001;37(2 Part 2):787-93.[Abstract/Free Full Text]
  • Krug AW, Schuster C., Gassner B. et al. Human epidermal growth factor receptor-1 expression renders Chinese hamster ovary cells sensitive to alternative aldosterone signaling. J Biol Chem 2002;277:45892-7.[Abstract/Free Full Text]
  • Krug AW, Grossmann C., Schuster C. et al.Aldosterone stimulates epidermal growth factor receptor (EGFR) expression. J Biol Chem 2003;278:43060-6.[Abstract/Free Full Text]
  • Qin W., Rudolph AE, Bond BR et al. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res 2003;93:69-76.[Abstract/Free Full Text]
  • Hafezi-Moghadam A., Simoncini T., Yang E. et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 2002;8:473-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Beggah AT, Escoubet B., Puttini S. et al. Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes. Proc Natl Acad Sci U S A 2002;99:7160-5.[Abstract/Free Full Text]
  • Christ M., Meyer C., Sippel K.,Wehling M. Rapid aldosterone signaling in vascular smooth muscle cells: involvement of phospholipase C, diacylglycerol and protein kinase C alpha. Biochem Biophys Res Commun 1995;213:123-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sato A., Liu JP, Funder JW Aldosterone rapidly represses protein kinase C activity in neonatal rat cardiomyocytes in vitro.Endocrinology 1997;138:3410-16.[Abstract/Free Full Text]
  • Good DW, George T., Watts BA 3rd. Aldosterone potentiates 1,25-dihydroxyvitamin D3 action in renal thick ascending limb via a nongenomic, ERK-dependent pathway. Am J Physiol Cell Physiol 2003;285:C1122-30.[Abstract/Free Full Text]
  • Wehling M., Spes CH, Win N. et al. Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab 1998; 83:3517-22.[Abstract/Free Full Text]
  • Ball AM, Sole MJ Oxidative stress and the pathogenesis of heart failure. Cardiol Clin 1998;16(4):665-6ix.[CrossRef][Medline] [Order article via Infotrieve]
  • Keith ME, Jeejeebhoy KN, Langer A. et al.A controlled clinical trial of vitamin E supplementation in patients with congestive heart failure. Am J Clin Nutr 2001;73:219-24.[Abstract/Free Full Text]
  • Sole MJ, Jeejeebhoy KN Conditioned nutritional requirements and the pathogenesis and treatment of myocardial failure. Curr Opin Clin Nutr Metab Care 2000;3:417-24.[CrossRef][Medline] [Order article via Infotrieve]
  • Singal PK, Khaper N., Farahmand F., Bello-Klein A. Oxidative stress in congestive heart failure. Curr Cardiol Rep 2000; 2:206-11.[Medline] [Order article via Infotrieve]
  • Cesselli D., Jakoniuk I., Barlucchi L. et al. Oxidative stressmediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ Res 2001;89:279-86.[Abstract/Free Full Text]
  • Tsutsui H., Ide T., Hayashidani S. et al. Enhanced generation of reactive oxygen species in the limb skeletal muscles from a murine infarct model of heart failure. Circulation 2001;104: 134-6.[Abstract/Free Full Text]
  • Haugen EN, Croatt AJ, Nath KA Angiotensin II induces renal oxidant stress in vivo and heme oxygenase-1 in vivo and in vitro. Kidney Int 2000;58:144-52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rajagopalan S., Kurz S., Munzel T. et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996;97:1916-23.[Web of Science][Medline] [Order article via Infotrieve]
  • Wang HD, Pagano PJ, Du Y. et al. Superoxide anion from the adventitia of the rat thoracic aorta inactivates nitric oxide. Circ Res 1998;82:810-18.[Abstract/Free Full Text]
  • Swei A., Lacy F., DeLano FA, Schmid-Schonbein GW Oxidative stress in the Dahl hypertensive rat. Hypertension 1997;30:1628-33.[Abstract/Free Full Text]
  • Laursen JB, Rajagopalan S., Galis Z.,Tarpey M., Freeman BA, Harrison DG Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 1997; 95:588-93.[Abstract/Free Full Text]
  • Kerr S., Brosnan MJ, McIntyre M., Reid JL, Dominiczak AF, Hamilton CA Superoxide anion production is increased in a model of genetic hypertension: role of the endothelium. Hypertension 1999;33:1353-8.[Abstract/Free Full Text]
  • Ide T., Tsutsui H., Kinugawa S. et al. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 1999;85:357-63.[Abstract/Free Full Text]
  • Nath R., Kumar D., Li T., Singal PK Metallothioneins, oxidative stress and the cardiovascular system. Toxicology 2000; 155:17-26.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Somers MJ, Mavromatis K., Galis ZS, Harrison DG Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation 2000;101:1722-8.[Abstract/Free Full Text]
  • Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986;320:454-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Schnackenberg CG,Wilcox CSTwo-week administration of tempol attenuates both hypertension and renal excretion of 8-Iso prostaglandin f2alpha. Hypertension 1999;33(1 Pt 2):424-8.[Abstract/Free Full Text]
  • Singal PK, Beamish RE, Dhalla NS Potential oxidative pathways of catecholamines in the formation of lipid peroxides and genesis of heart disease. Adv Exp Med Biol 1983;161:391-401.[Web of Science][Medline] [Order article via Infotrieve]
  • Griendling KK, Sorescu D., Lassegue B., Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 2000;20: 2175-83.[Abstract/Free Full Text]
  • Virdis A., Neves MF, Amiri F., Viel E.,Touyz RM, Schiffrin EL Spironolactone improves angiotensin-induced vascular changes and oxidative stress.Hypertension 2002;40:504-10.[Abstract/Free Full Text]
  • Pu Q., Neves MF, Virdis A., Touyz RM, Schiffrin EL Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 2003;42:49-55.[Abstract/Free Full Text]
  • Sun Y., Zhang J., Lu L., Chen SS, Quinn MT, Weber KT Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 2002;161:1773-81.[Abstract/Free Full Text]
  • Li JS, Lariviere R., Schiffrin EL Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. Hypertension 1994; 24:183-8.[Abstract/Free Full Text]
  • Tostes RC, Touyz RM, He G., Chen X., Schiffrin EL Contribution of endothelin-1 to renal activator protein-1 activation and macrophage infiltration in aldosterone-induced hypertension. Clin Sci (Lond) 2002;103(suppl 48):25S-30S.[Medline] [Order article via Infotrieve]
  • Cambiaggi C., Mencarelli M., Muscettola M., Grasso G. Gene expression of endothelin-1 (ET-1) and release of mature peptide by activated human neutrophils. Cytokine 2001; 14:230-3.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Scholz H., Kramer BK, Hamann M., Gotz KH, Kurtz A. Effects of endothelins on renin secretion from rat kidneys. Acta Physiol Scand 1995;155:173-82.[Web of Science][Medline] [Order article via Infotrieve]
  • Rossi GP, Sacchetto A., Cesari M., Pessina AC Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc Res 1999;43:300-07.[Abstract/Free Full Text]
  • Keidar S., Hayek T., Kaplan M. et al. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2003;41:955-63.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Farquharson CA, Struthers AD Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:594-7.[Abstract/Free Full Text]
  • Williams JS,Williams GH 50th anniversary of aldosterone. J Clin Endocrinol Metab 2003;88:2364-72.[Free Full Text]
  • Anker SD, Chua TP, Ponikowski P. et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997;96: 526-34.[Abstract/Free Full Text]
  • Weber KT Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689-97.[Free Full Text]
  • Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429-35.[Abstract]
  • Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.[Abstract]
  • MacFadyen RJ, Lee AF, Morton JJ, Pringle SD, Struthers AD How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 1999;82:57-61.[Abstract/Free Full Text]
  • McKelvie RS, Yusuf S., Pericak D. et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators.Circulation 1999;100:1056-64.[Abstract/Free Full Text]
  • Staessen J., Lijnen P., Fagard R., Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981;91:457-65.[Abstract/Free Full Text]
  • Cohn JN,Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.[Abstract/Free Full Text]
  • McMurray JJ, Ostergren J., Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362: 767-71.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pitt B., Zannad F., Remme WJ et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.[Abstract/Free Full Text]
  • Brilla CG, Matsubara LS, Weber KT Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993;25: 563-75.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Brilla CG, Pick R.,Tan LB, Janicki JS,Weber KT Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990;67:1355-64.[Abstract/Free Full Text]
  • Brilla CG, Weber KT Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 1992;26:671-7.[Abstract/Free Full Text]
  • Lacolley P., Labat C., Pujol A., Delcayre C., Benetos A., Safar M. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation 2002;106:2848-53.[Abstract/Free Full Text]
  • ChunTY, Bloem LJ, Pratt JH Aldosterone inhibits inducible nitric oxide synthase in neonatal rat cardiomyocytes. Endocrinology 2003;144:1712-17.[Abstract/Free Full Text]
  • Lijnen P., Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 2000;32:865-79.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Fullerton MJ, Funder JW Aldosterone and cardiac fibrosis: in vitro studies. Cardiovasc Res 1994;28:1863-7.[Abstract/Free Full Text]
  • Ullian ME, Walsh LG, Morinelli TA Potentiation of angiotensin II action by corticosteroids in vascular tissue. Cardiovasc Res 1996;32:266-73.[Abstract/Free Full Text]
  • Brilla CG, Zhou G., Matsubara L.,Weber KT Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994;26: 809-20.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Saksela O., Rifkin DB Cell-associated plasminogen activation: regulation and physiological functions. Annu Rev Cell Biol 1988;4:93-126.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Alexander CM, Werb Z. Proteinases and extracellular matrix remodeling. Curr Opin Cell Biol 1989;1:974-82.[CrossRef][Medline] [Order article via Infotrieve]
  • Eitzman DT, McCoy RD, Zheng X. et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996;97:232-7.[Web of Science][Medline] [Order article via Infotrieve]
  • Ullian ME, Schelling JR, Linas SL Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension 1992;20:67-73.[Abstract/Free Full Text]
  • Brown NJ, Kim KS, Chen YQ et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 2000;85:33644.
  • Rocha R., Rudolph AE, Frierdich GE et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002;283:H1802-H1810.[Abstract/Free Full Text]
  • Rocha R., Martin-Berger CL, Yang P., Scherrer R., Delyani J., McMahon E. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002;143:4828-36.[Abstract/Free Full Text]
  • Robert V., Heymes C., Silvestre JS, Sabri A., Swynghedauw B., Delcayre C. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension 1999;33:981-6.[Abstract/Free Full Text]
  • Benitah JP, Vassort G. Aldosterone upregulates Ca(2+) current in adult rat cardiomyocytes. Circ Res 1999;85:1139-45.[Abstract/Free Full Text]
  • Molkentin JD, Lu JR,Antos CL et al.A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998;93:215-28.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Takeda Y., Yoneda T., Demura M., Usukura M., Mabuchi H. Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy. Circulation 2002;105:677-9.[Abstract/Free Full Text]
  • Xiao F., Puddefoot JR, Vinson GP Aldosterone mediates angiotensin II-stimulated rat vascular smooth muscle cell proliferation. J Endocrinol 2000;165:533-6.[Abstract]
  • Neumann S., Huse K., Semrau R. et al. Aldosterone and D-glucose stimulate the proliferation of human cardiac myofibroblasts in vitro. Hypertension 2002;39:756-60.[Abstract/Free Full Text]
  • Takeda Y., Yoneda T., Demura M., Miyamori I., Mabuchi H. Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy. Endocrinology 2000;141:1901-04.[Abstract/Free Full Text]
  • Delles C., Schmidt BM, Muller HJ, Oehmer S., Klingbeil AU, Schmieder RE Functional relevance of aldosterone for the determination of left ventricular mass. Am J Cardiol 2003;91: 297-301.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wencker D., Chandra M., Nguyen K. et al. A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 2003;111:1497-504.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Leri A., Claudio PP, Li Q. et al. Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. J Clin Invest 1998; 101:1326-42.[Web of Science][Medline] [Order article via Infotrieve]
  • De Angelis N., Fiordaliso F., Latini R. et al. Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive rat. J Mol Cell Cardiol 2002; 34:1655-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ben Rhouma K., Schimchowitsch S., Stoeckel ME, Felix JM, Sakly M. [Implication of type II glucocorticoid receptors in aldosterone induced apoptosis of rat thymocytes]. Arch Physiol Biochem 1997;105:216-24.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • McCullers DL, Sullivan PG, Scheff SW, Herman JP Mifepristone protects CA1 hippocampal neurons following traumatic brain injury in rat. Neuroscience 2002;109:219-30.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sam F., Kerstetter DL, Ooi H. et al. Mice lacking osteopontin exhibit increased left ventricular dilation and reduced fibrosis after aldosterone infusion. Am J Hypertens 2004; 17:188-93.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ramires FJ, Mansur A., Coelho O. et al. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 2000;85:1207-11.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hallstrom A., Pratt CM, Greene HL et al. Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: analysis of the Cardiac Arrhythmia Suppression Trial. J Am Coll Cardiol 1995;25:1250-7.[Abstract]
  • Zannad F. Angiotensin-converting enzyme inhibitor and spironolactone combination therapy. New objectives in congestive heart failure treatment. Am J Cardiol 1993;71:34A-39A.[CrossRef][Medline] [Order article via Infotrieve]
  • Barr CS, Lang CC, Hanson J., Arnott M., Kennedy N., Struthers AD Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76:1259-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Weber MA, Purdy RE Catecholamine-mediated constrictor effects of aldosterone on vascular smooth muscle. Life Sci 1982;30:2009-17.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Zannad F., Alla F., Dousset B., Perez A., Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000;102:2700-06.[Abstract/Free Full Text]
  • Pitt B., Reichek N., Willenbrock R. et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003; 108:1831-8.[Abstract/Free Full Text]
  • Gerstein HC, Mann JF, Yi Q. et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421-6.[Abstract/Free Full Text]
  • Epstein M., Buckalew V., Altamirano J., Roniker B., Krause S., Kleiman J. Eplerenone Reduces Proteinuria in Type II Diabetes Mellitus: Implications for Aldosterone Involvement in the Pathogenesis of Renal Dysfunction. JACC 2002;39(suppl 1): 249A.
  • Pitt B., Remme W., Zannad F., Neaton J. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.[Abstract/Free Full Text]
  • Rabasseda X., Silvestre J., Castaner J. Eplerenone: antihypertensive treatment of heart failure: aldosterone antagonist. Drugs Future 1999;24:488-501.[CrossRef]
  • Funder JW Aldosterone resurgens--letter from EPHESUS. J Clin Endocrinol Metab 2003;88:2373-5.[Free Full Text]
  • Weinberger MH Salt sensitivity of blood pressure in humans. Hypertension 1996;27(3 Pt 2):481-90.[Abstract/Free Full Text]
  • Pratt JH, Rebhun JF, Zhou L. et al. Levels of mineralocorticoids in whites and blacks. Hypertension 1999;34:315-19.[Abstract/Free Full Text]
  • Yancy CW Heart failure in blacks: etiologic and epidemiologic differences. Curr Cardiol Rep 2001;3:191-7.[Medline] [Order article via Infotrieve]
  • Flack JM, Oparil S., Pratt JH et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients.JAm Coll Cardiol 2003;41:1148-55.[Abstract/Free Full Text]
  • Weinberger MH, Roniker B., Krause SL, Weiss RJ Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.AmJHypertens 2002;15:709-16.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Krum H., Nolly H.,Workman D. et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002;40:117-23.[Abstract/Free Full Text]
  • Takeda Y., Miyamori I., Yoneda T. et al. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab 1996;81:2797-800.[Abstract/Free Full Text]
  • Hatakeyama H., Miyamori I., Fujita T., Takeda Y., Takeda R., Yamamoto H. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. JBiol Chem 1994;269:24316-20.[Abstract/Free Full Text]
  • Gomez-Sanchez CE, Zhou MY, Cozza EN, Morita H., Foecking MF, Gomez-Sanchez EP Aldosterone biosynthesis in the rat brain. Endocrinology 1997;138:3369-73.[Abstract/Free Full Text]
  • Takeda Y., Miyamori I.,YonedaT. et al. Production of aldosterone in isolated rat blood vessels. Hypertension 1995;25:170-3.[Abstract/Free Full Text]
  • Patel PD, Sherman TG, Goldman DJ, Watson SJ Molecular cloning of a mineralocorticoid (type I) receptor complementary DNA from rat hippocampus. Mol Endocrinol 1989;3:1877-85.[Abstract/Free Full Text]
  • Pearce P., Funder JW High affinity aldosterone binding sites (type I receptors) in rat heart. Clin Exp Pharmacol Physiol 1987;14(11-12):859-66.[Web of Science][Medline] [Order article via Infotrieve]
  • TakedaY., Miyamori I., Inaba S. et al.Vascular aldosterone in genetically hypertensive rats. Hypertension 1997;29(1 Pt 1): 45-8.[Abstract/Free Full Text]
  • Benetos A., Lacolley P., Safar ME Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 1997;17:1152-6.[Abstract/Free Full Text]
  • Young M., Head G., Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 1995;269(4 Pt 1):E657-E662.[Web of Science][Medline] [Order article via Infotrieve]
  • Ikeda U., Kanbe T., Nakayama I., Kawahara Y., Yokoyama M., Shimada K. Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta. Eur J Pharmacol 1995;290:69-73.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Farquharson CA, Struthers AD Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an 425-31.
  • Duprez DA, De Buyzere ML, Rietzschel ER et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998;19:1371-6.[Abstract/Free Full Text]
  • Blacher J., Amah G., Girerd X. et al. Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens 1997;10(12 Pt 1):1326-34.[Web of Science][Medline] [Order article via Infotrieve]
  • White PC, Slutsker L. Haplotype analysis of CYP11B2. Endocr Res 1995;21:437-442.[Web of Science][Medline] [Order article via Infotrieve]
  • Kupari M., Hautanen A., Lankinen L. et al. Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation 1998;97:569-75.[Abstract/Free Full Text]
  • Brand E., Chatelain N., Mulatero P. et al. Structural analysis and evaluation of the aldosterone synthase gene in hypertension.Hypertension 1998;32:198-204.[Abstract/Free Full Text]
  • Lajemi M., Labat C., Gautier S. et al.Angiotensin II type 1 receptor-153A/G and 1166A/C gene polymorphisms and increase in aortic stiffness with age in hypertensive subjects. J Hypertens 2001;19:407-13.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Takai E., Akita H., Kanazawa K. et al. Association between aldosterone synthase (CYP11B2) gene polymorphism and left ventricular volume in patients with dilated cardiomyopathy. Heart 2002;88:649-50.[Free Full Text]
  • Tiago AD, Badenhorst D., Skudicky D. et al.An aldosterone synthase gene variant is associated with improvement in left ventricular ejection fraction in dilated cardiomyopathy. Cardiovasc Res 2002;54:584-9.[Abstract/Free Full Text]
  • Sato A., Funder JW High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes. Endocrinology 1996;137:4145-53.[Abstract]
  • Trueblood NA, Xie Z., Communal C. et al. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ Res 2001;88:1080-7.[Abstract/Free Full Text]
  • Campos AH, Zhao Y., Pollman MJ, Gibbons GH DNA microarray profiling to identify angiotensin-responsive genes in vascular smooth muscle cells: potential mediators of vascular disease. Circ Res 2003;92:111-18.[Abstract/Free Full Text]
  • Gerling IC, Sun Y., Ahokas RA et al. Aldosteronism: an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype. Am J Physiol Heart Circ Physiol 2003;285:H813-H821.[Abstract/Free Full Text]
  • Ahokas RA,Warrington KJ, Gerling IC et al.Aldosteronism and Peripheral Blood Mononuclear Cell Activation. A Neuroendocrine-Immune Interface. Circ Res 2003;93:124-35.[Abstract/Free Full Text]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 5, No. 1, 3-13 (2004)
DOI: 10.3317/jraas.2004.005
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 HypertensionHome page
J. Blanco-Rivero, V. Cachofeiro, V. Lahera, R. Aras-Lopez, I. Marquez-Rodas, M. Salaices, F. E. Xavier, M. Ferrer, and G. Balfagon
Participation of Prostacyclin in Endothelial Dysfunction Induced by Aldosterone in Normotensive and Hypertensive Rats
Hypertension, July 1, 2005; 46(1): 107 - 112.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Shieh, F. K
Right arrow Articles by Sam, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shieh, F. K
Right arrow Articles by Sam, F.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Heart Failure
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement